JBIO News and Press, Jade Biosciences Inc.

2026-03-06 14:07:02 ET More on Jade Biosciences, Inc. Seeking Alpha’s Quant Rating on Jade Biosciences, Inc. Historical earnings data for Jade Biosciences, Inc. Dividend scorecard for Jade Biosciences, Inc. Read the full article on Seeking Alpha ...

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected t...

2026-02-27 17:37:50 ET Jade Biosciences, Inc. (JBIO) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 1:20 PM EST... Read the full article on Seeking Alpha For further details see: Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual...

2026-01-16 12:26:03 ET Jade Biosciences, Inc. (JBIO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 2:15 PM EST... Read the full article on Seeking Alpha For further details see: Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Con...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026  Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027 JADE201, a half-life extended afucosylate...

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ...

2025-11-13 17:45:01 ET More on Jade Biosciences, Inc. Jade Biosciences offers $135 million equity through private placement Seeking Alpha’s Quant Rating on Jade Biosciences, Inc. Historical earnings data for Jade Biosciences, Inc. Dividend scorecard fo...

Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in-class selective anti-APRIL monoclonal antibody for IgA nephropathy ...

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presen...